目次
Table of Content
1. Introduction to LAG-3 Targeting Therapies
1.1 LAG-3 As Therapeutic Target
1.2 LAG-3 Targeting Therapies - Mechanism Of Action
1.3 LAG-3 Targeting Approaches
2. Combination Strategies For LAG-3 Targeting Therapies
3. Global LAG-3 Targeting Therapy Market Scenario
3.1 Current Market Outlook
3.2 Future Market Outlook
4. LAG-3 Targeting Therapy Market Regional Analysis
4.1 US
4.2 EU
4.3 China
4.4 Australia
4.5 UK
4.6 Japan
4.7 Canada
4.8 South Korea
5. LAG-3 Targeting Therapy - Development Trends By Indication
5.1 Cancer
5.1.1 Lymphoma
5.1.2 Melanoma
5.1.3 Lung Cancer
5.1.4 Gastrointestinal Cancers
5.1.5 Head and Neck Cancer
5.2 Autoimmune and Inflammatory Diseases
5.3 Microbial Infections
6. Opdualag (Nivolumab and Relatlimab) - Overview, Pricing, Dosing and Sales Analysis
6.1 Overview and Patent Insight
6.2 Pricing and Dosing
6.3 Sales Insight
7. Global LAG-3 Targeting Therapies Clinical Trials Overview
7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
7.6 Patient Segment
8. Global LAG3 Targeting Therapies clinical Trials Insight By Company, Country, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III
9. Marketed LAG-3 Inhibitor Clinical Insight
10. Global LAG-3 Targeting Therapy Market Dynamics
10.1 Market Drivers
10.2 Market Challenges
11. Competitive Landscape
11.1 ABL Bio
11.2 Agenus
11.3 Akeso Biopharma
11.4 Bristol-Myers Squibb
11.5 EpimAb Biotherapeutics
11.6 F-star Therapeutics
11.7 Immutep
11.8 Innovent Biologics
11.9 Shanghai Henlius Biotech
11.10 Y-Biologics
List of Figures
Figure 1-1: LAG-3/MHC Class II Signaling Pathway
Figure 1-2: LAG-3 Targeted Therapy Landscape - Milestones
Figure 1-3: LAG-3 Inhibitor - Mechanism Of Action
Figure 1-4: LAG-3 Agonist - Mechanism Of Action
Figure 1-5: LAG-3 Depletion - Mechanism Of Action
Figure 1-6: Bispecific Antibodies - Binding Efficacy
Figure 2-1: Overview to LAG-3 Combinations
Figure 3-1: Global - LAG 3 Targeting Therapy Market Value (US$ Million), 2022-2024
Figure 3-2: Global - LAG 3 Targeting Therapy Market Value By Region (US$ Million), 2024
Figure 3-3: Global - LAG 3 Targeting Therapy Market Value By Region (%), 2024
Figure 3-4: Global - Quarterly LAG 3 Targeting Therapy Market Value (US$ Million), 2024
Figure 3-5: Global - LAG 3 Targeting Therapy Market Forecast (US$ Million), 2025 - 2030
Figure 3-6: Global LAG-3 Targeting Therapy Market - Future Outlook
Figure 4-1: EU - Research Institutes and Hospitals Conducting LAG-3 Therapy Clinical Trials
Figure 5-1: RELATIVITY-069 Phase 1/2 (NCT05255601) Study - Initiation and Completion Year
Figure 5-2: AK129-102 Phase 1/2 (NCT06642792) Study - Initiation and Completion Year
Figure 5-3: R3767-ONC-2011 Phase 3 (NCT05352672) Study - Initiation and Completion Year
Figure 5-4: R3767-ONC-2055 Phase 3 (NCT05352672) Study - Initiation and Completion Year
Figure 5-5: INCAGN 2385-201 Phase 1/2 (NCT04370704) Study - Initiation and Completion Year
Figure 5-6: R3767-ONC-2235 Phase 2/3 (NCT05785767) Study - Initiation and Completion Year
Figure 5-7: R3767-ONC-2236 Phase 2/3 (NCT05800015) Study - Initiation and Completion Year
Figure 5-8: R2810-ONC-1866 Phase 2 (NCT03916627) Study - Initiation and Completion Year
Figure 5-9: R2810-ONC-2266 Phase 2 (NCT06161441) Study - Initiation and Completion Year
Figure 5-10: RELATIVITY-104 Phase 2 (NCT04623775) Study - Initiation and Completion Year
Figure 5-11: RELATIVITY-1093 Phase 3 (NCT06561386) Study - Initiation and Completion Year
Figure 5-12: J23155 Phase 2 (NCT06205836) Study - Initiation and Completion Year
Figure 5-13: J1714 Phase 1b (NCT03044613) Study - Initiation and Completion Year
Figure 5-14: RELATIVITY-123 Phase 3 (NCT05328908) Study - Initiation and Completion Year
Figure 5-15: NP41300 Phase 1/2 (NCT04140500) Study - Initiation and Completion Year
Figure 5-16: LBL-007-CN-003 Phase 1b/2 (NCT05102006) Study - Initiation and Completion Year
Figure 5-17: HCC 18-139 Phase 2 (NCT04080804) Study - Initiation and Completion Year
Figure 5-18: IMP761-P001 Phase 1 (NCT06637865) Study - Initiation and Completion Year
Figure 6-1: Opdualag - Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Year By Region
Figure 6-3: US - Cost Per Unit and Supply Of Opdualag (US$), April’2025
Figure 6-4: Cost Per Unit and Supply Of Opdualag (US$), April’2025
Figure 6-5: Global - Opdualag Annual Sales (US$ Million), 2022-2024
Figure 6-6: Global - Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 6-7: Opdualag - US v/s ROW Sales (US$ Million), 2024
Figure 6-8: Global - Opdualag Sales (US$ Million), 2024
Figure 6-9: US - Opdualag Sales (US$ Million), 2022-2024
Figure 6-10: US - Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 6-11: ROW - Opdualag Sales (US$ Million), 2022-2024
Figure 6-12: ROW - Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 7-1: Global - LAG-3 Inhibitor Clinical Trials By Phase (Numbers), 2025 - 2030
Figure 7-2: Global - LAG-3 Inhibitor Clinical Trials By Country (Numbers), 2025 - 2030
Figure 7-3: Global - LAG-3 Inhibitor Clinical Trials By Company (Numbers), 2025 - 2030
Figure 7-4: Global - LAG-3 Inhibitor Clinical Trials By Indication (Numbers), 2025 - 2030
Figure 7-5: Global - LAG-3 Inhibitor Clinical Trials By Priority Status (Numbers), 2025 - 2030
Figure 7-6: Global - LAG-3 Inhibitor Clinical Trials By Patient Segment (Numbers), 2025 - 2030
Figure 10-1: Global LAG-3 Targeting Therapy Market - Drivers and Opportunities
Figure 10-2: Global LAG-3 Targeting Therapy Market - Challenges and Restraints
List of Tables
Table 2-1: Ongoing Preclinical and Clinical Trials For Combination of LAG-3 inhibitors, April’2025
Table 4-1: US - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April’2025
Table 4-2: China - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April’2025
Table 4-3: Immutep - Active Patents By Region
Table 5-1: Melanoma - Some Ongoing Clinical Trials For LAG-3 Inhibitors, April’2025
Table 6-1: Opdualag - Maximum Infusion Volumes and Concentration Ranges By Patient Group
Table 6-2: Opdualag - Recommended Dosage Modifications For Adverse Reactions
